1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 1,390 | 1,510 | 12:42 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 12:36 | Abbisko Therapeutics Co., Ltd.: Abbisko Therapeutics' CSF-1R Inhibitor Pimicotinib Approved by the China NMPA, Addressing the Treatment Gap for Tenosynovial Giant Cell Tumor | 2 | GlobeNewswire (USA) | ||
| 09:30 | ABBISKO-B (02256): INSIDE INFORMATION - ABBISKO THERAPEUTICS' CSF-1R INHIBITOR PIMICOTINIB APPROVED BY THE CHINA NMPA | 1 | HKEx | ||
| Di | ABBISKO-B (02256): VOLUNTARY ANNOUNCEMENT - ABBISKO THERAPEUTICS COMPLETES FIRST PATIENT DOSING OF ABSK061, FGFR2/3 INHIBITOR, FOR THE TREATMENT OF ACHONDROPLASIA | 1 | HKEx | ||
| ABBISKO CAYMAN Aktie jetzt für 0€ handeln | |||||
| 08.12. | ABBISKO-B (02256): VOLUNTARY ANNOUNCEMENT - ABBISKO THERAPEUTICS PRESENTS PRELIMINARY PHASE II RESULTS OF ORAL PD-L1 INHIBITOR ABSK043 COMBINED WITH EGFR ... | 1 | HKEx | ||
| 01.12. | ABBISKO-B (02256): VOLUNTARY ANNOUNCEMENT - IND CLEARANCE FROM THE FDA FOR ORAL SMALL MOLECULE KRAS G12D INHIBITOR ABSK141 | 1 | HKEx | ||
| 17.11. | ABBISKO-B (02256): VOLUNTARY ANNOUNCEMENT - ABBISKO THERAPEUTICS PRESENTS LONGER-TERM EFFICACY AND SAFETY OUTCOMES FROM PHASE III MANEUVER STUDY OF PIMICOTINIB ... | 1 | HKEx | ||
| 03.11. | ABBISKO-B (02256): VOLUNTARY ANNOUNCEMENT - ABBISKO THERAPEUTICS COMPLETES FIRST PATIENT DOSING IN A PHASE II STUDY OF ABSK043, AN ORAL SMALL-MOLECULE ... | 1 | HKEx | ||
| 27.10. | Goldman Sachs initiates Abbisko Therapeutics stock with Buy rating | 3 | Investing.com | ||
| 27.10. | ABBISKO-B (02256): VOLUNTARY ANNOUNCEMENT - ABBISKO THERAPEUTICS PRESENTED PRECLINICAL FINDINGS ON NOVEL CDK4/2 INHIBITOR AND SMARCA2 PROTAC DEGRADER ... | 1 | HKEx | ||
| 20.10. | ABBISKO-B (02256): VOLUNTARY ANNOUNCEMENT - ABBISKO THERAPEUTICS PRESENTS LONGER-TERM EFFICACY AND SAFETY OUTCOMES FROM PHASE III MANEUVER TRIAL OF PIMICOTINIB ... | 1 | HKEx | ||
| 29.09. | ABBISKO-B (02256): GRANT OF OPTIONS UNDER THE POST-IPO SHARE OPTION SCHEME AND GRANT OF RSUS UNDER THE 2019 SHARE INCENTIVE PLAN | 1 | HKEx | ||
| 15.09. | ABBISKO-B (02256): 2025 INTERIM REPORT | 3 | HKEx | ||
| 28.08. | ABBISKO-B (02256): DISCLOSEABLE TRANSACTION - SUBSCRIPTIONS OF WEALTH MANAGEMENT PRODUCTS | - | HKEx | ||
| 27.08. | ABBISKO-B (02256): NEXT DAY DISCLOSURE RETURNS | - | HKEx | ||
| 20.08. | ABBISKO-B (02256): VOLUNTARY ANNOUNCEMENT - IND CLEARANCE FROM THE CDE FOR ABBISKO THERAPEUTICS' ORAL PD-L1 INHIBITOR ABSK043 IN COMBINATION WITH KRAS ... | 1 | HKEx | ||
| 20.08. | ABBISKO-B (02256): NEXT DAY DISCLOSURE RETURNS | 2 | HKEx | ||
| 05.08. | ABBISKO-B (02256): NEXT DAY DISCLOSURE RETURNS | - | HKEx | ||
| 04.08. | ABBISKO-B (02256): TERMS OF REFERENCE FOR THE NOMINATION COMMITTEE | 1 | HKEx | ||
| 04.08. | ABBISKO-B (02256): INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30, 2025 | 1 | HKEx | ||
| 23.07. | ABBISKO-B (02256): VOLUNTARY ANNOUNCEMENT - ABBISKO THERAPEUTICS DOSES FIRST PATIENT IN PHASE 1 CLINICAL TRIAL FOR ABSK131, A NOVEL PRMT5*MTA INHIBITOR | 3 | HKEx |
1 2 Weiter >>
25 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| NURIX THERAPEUTICS | 18,520 | 0,00 % | Nurix Therapeutics, Inc.: Nurix Therapeutics Appoints Accomplished Biopharmaceutical Leader Roger Dansey, M.D., to Its Board of Directors | SAN FRANCISCO, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of... ► Artikel lesen | |
| DISC MEDICINE | 80,04 | -11,50 % | Stifel reaffirms Buy rating on Disc Medicine stock amid FDA review speculation | ||
| DYNE THERAPEUTICS | 19,850 | 0,00 % | Dyne Therapeutics, Inc.: Dyne Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares | WALTHAM, Mass., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven... ► Artikel lesen | |
| TAYSHA GENE THERAPIES | 5,490 | +0,73 % | Citizens reiterates Market Outperform rating on Taysha Gene Therapies stock | ||
| SUMMIT THERAPEUTICS | 17,820 | 0,00 % | Summit Therapeutics stock rating reiterated by Cantor Fitzgerald | ||
| RELAY THERAPEUTICS | 8,400 | 0,00 % | Relay Therapeutics, Inc.: Relay Therapeutics Announces Efficacy Subset Analysis of Zovegalisib (RLY-2608) + Fulvestrant in Breast Cancer Patients Pre-Treated with SERD or with ESR1 Mutations at SABCS 2025 | Efficacy data remain consistent with previous disclosures, showing 10.3-month median PFS in all patients and 11.4-month median PFS in 2L patients Subset analyses show broad activity in patients with... ► Artikel lesen | |
| IMMUNEERING | 5,650 | 0,00 % | Immuneering Corporation: Immuneering Advances Towards Dosing First Patient in Phase 3 Atebimetinib Trial for First-Line Metastatic Pancreatic Cancer Patients, Securing Alignment with FDA and EMA | - End-of-Phase 2 interactions with FDA complete; scientific advice received from EMA - - Company expects to dose first patient in global Phase 3 registrational trial, MAPKeeper 301, in mid-2026 -... ► Artikel lesen | |
| TREVI THERAPEUTICS | 13,010 | 0,00 % | Potenzial von Hustenmedikament: Stifel erhöht Kursziel für Trevi Therapeutics auf 18 Dollar | ||
| VIR BIOTECHNOLOGY | 5,760 | 0,00 % | EQS-News: Norgine Pharmaceuticals Limited: Norgine erweitert sein Hepatologie- und Spezialitätenportfolio durch exklusive Einlizenzierungsvereinbarung mit Vir Biotechnology | EQS-News: Norgine Pharmaceuticals Limited
/ Schlagwort(e): Produkteinführung/Vereinbarung
Norgine erweitert sein Hepatologie- und Spezialitätenportfolio durch exklusive Einlizenzierungsvereinbarung... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 72,32 | 0,00 % | Avidity Biosciences, Inc.: Avidity Biosciences Reports Third Quarter 2025 Financial Results and Recent Highlights | Announced Novartis agreement to acquire Avidity for total equity value of approximately $12 billion; Avidity expects to separate its early-stage precision cardiology... ► Artikel lesen | |
| ABSCI | 3,380 | -0,88 % | Absci Partners With Oracle And AMD To Accelerate AI-Driven Drug Discovery | SUNNYVALE (dpa-AFX) - Absci, a clinical-stage biotech focused on AI-powered therapeutics, announced a collaboration with Oracle Cloud Infrastructure - OCI and Advanced Micro Devices, Inc. (AMD)... ► Artikel lesen | |
| COGENT BIOSCIENCES | 39,580 | 0,00 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Positive Top-line Results of APEX Trial of Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM) | -- Bezuclastinib demonstrated rapid and deep clinical benefit in AdvSM patients resulting in an objective response rate (CR+CRh+PR+CI) of 57% per mIWG criteria and 80% per PPR criteria -- -- Bezuclastinib... ► Artikel lesen | |
| VOR BIOPHARMA | 12,410 | 0,00 % | Vor Biopharma Inc. - 8-K, Current Report | ||
| ARVINAS | 11,680 | 0,00 % | Arvinas Inc.: Arvinas Presents Late Breaking, Positive Phase 1 Clinical Data for ARV-102, a PROTAC LRRK2 Degrader, at the 2025 International Congress of Parkinson's Disease and Movement Disorders | - ARV-102 was well tolerated in clinical trials for both healthy volunteers and patients with Parkinson's disease - - ARV-102 demonstrated dose-dependent cerebrospinal fluid (CSF) exposure in subjects... ► Artikel lesen |
Das Unternehmen ABBISKO CAYMAN LTD kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von -0,020 (-1,41 %) liegt der Kurs bei 1,400 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ABBISKO CAYMAN LTD finden Sie auf Wallstreet Online.